Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cancer Survival in Reunion Island , 1998-2008 (SUCRE) (SUCRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02900287
Recruitment Status : Not yet recruiting
First Posted : September 14, 2016
Last Update Posted : September 5, 2018
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de la Réunion

Brief Summary:
Cancer survival is important to determine prognostic of patients and evaluate care and prevention health strategies. Sucre is the first study to describe cancer survival in Reunion Island. Sucre aims at evaluating five year cancer prognostic in Reunion Island by cancer site and gender. Sucre is a retrospective cohort study of cancer diagnosed between 01/01/1998 and 31/12/2008.

Condition or disease
Neoplasms

Detailed Description:
Data are extracted from Reunion Island Cancer Registry.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 18000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Survie Des Personnes Atteintes de Cancer à la Réunion, 1998-2008 (SUCRE)
Estimated Study Start Date : January 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019



Primary Outcome Measures :
  1. 5 years related survival rate by cancer site and gender [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. 1, 3, 5 and 10 years related survival rate by cancer site and gender [ Time Frame: 1, 3, 5 and 10 years ]
  2. 1, 3, 5 and 10 years standardised survival rate by cancer site and gender [ Time Frame: 1, 3, 5 and 10 years ]
  3. 1, 3, 5 and 10 years related survival rate by age at diagnosis [ Time Frame: 1, 3, 5 and 10 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Study population extracted from Reunion Island Cancer Registry
Criteria

Inclusion Criteria:

  • Patients domiciled in Reunion Island at diagnosis
  • Patients with at least 15 years of age at diagnosis
  • Patients with cancer diagnosis between 01/01/1998 and 31/12/2008

Exclusion Criteria:

  • Cutaneous malignant cancer expected melanoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02900287


Contacts
Layout table for location contacts
Contact: Emmanuel CHIRPAZ 02 62 90 51 23 emmanuel.chirpaz@chu-reunion.fr

Sponsors and Collaborators
Centre Hospitalier Universitaire de la Réunion

Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de la Réunion
ClinicalTrials.gov Identifier: NCT02900287     History of Changes
Other Study ID Numbers: 2014/CHU/05
First Posted: September 14, 2016    Key Record Dates
Last Update Posted: September 5, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Centre Hospitalier Universitaire de la Réunion:
Survival
Cancer